Resource Summary Report

Generated by RRID on Jul 31, 2026

Anti-Bim Antibody, Unconjugated

RRID:AB_10692515
Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 2819, RRID:AB_10692515

Antibody Information

URL: http://antibodyregistry.org/AB_10692515

Proper Citation: Cell Signaling Technology Cat# 2819, RRID:AB_10692515

Target Antigen: Bim

Clonality: unknown

Comments: Applications: W, IP. Consolidation on 10/2018: AB_10692515, AB_659953.

Antibody Name: Anti-Bim Antibody, Unconjugated

Description: This unknown targets Bim

Target Organism: monkey, simian, mouse, human

Antibody ID: AB_10692515

Vendor: Cell Signaling Technology

Catalog Number: 2819

Record Creation Time: 20250820T014811+0000

Record Last Update: 20250820T115348+0000

Ratings and Alerts

No rating or validation information has been found for Anti-Bim Antibody, Unconjugated.

No alerts have been found for Anti-Bim Antibody, Unconjugated.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 18 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Matkar S, et al. (2025) Kinome Reprogramming of G2/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven Neuroblastoma. Molecular cancer therapeutics, 24(9), 1389.

Baro M, et al. (2025) Redundancy of the OST catalytic subunit facilitates therapeutic targeting of N-glycosylation. Cell chemical biology, 32(6), 839.

Van Der Byl W, et al. (2024) The CD8+ T cell tolerance checkpoint triggers a distinct differentiation state defined by protein translation defects. Immunity, 57(6), 1324.

Pieper NM, et al. (2024) Inhibition of bromodomain and extra-terminal proteins targets constitutively active NF?B and STAT signaling in lymphoma and influences the expression of the antiapoptotic proteins BCL2A1 and c-MYC. Cell communication and signaling : CCS, 22(1), 415.

Perurena N, et al. (2023) USP9X mediates an acute adaptive response to MAPK suppression in pancreatic cancer but creates multiple actionable therapeutic vulnerabilities. Cell reports. Medicine, 4(4), 101007.

Mertens S, et al. (2023) Drug-repurposing screen on patient-derived organoids identifies therapy-induced vulnerability in KRAS-mutant colon cancer. Cell reports, 42(4), 112324.

Liu Y, et al. (2023) Artesunate, a new antimalarial clinical drug, exhibits potent anti-AML activity by targeting the ROS/Bim and TFRC/Fe2+ pathways. British journal of pharmacology, 180(6), 701.

Pan R, et al. (2022) Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis. Cell, 185(9), 1521.

Cai J, et al. (2022) High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition. Cell reports, 40(4), 111095.

Loo LSW, et al. (2020) BCL-xL/BCL2L1 is a critical anti-apoptotic protein that promotes the survival of differentiating pancreatic cells from human pluripotent stem cells. Cell death & disease, 11(5), 378.

Pearson JM, et al. (2020) Ceramide Analogue SACLAC Modulates Sphingolipid Levels and MCL-1 Splicing to Induce Apoptosis in Acute Myeloid Leukemia. Molecular cancer research : MCR, 18(3), 352.

Zierhut C, et al. (2019) The Cytoplasmic DNA Sensor cGAS Promotes Mitotic Cell Death. Cell, 178(2), 302.

Burmi RS, et al. (2019) Combined inhibition of the PI3K/mTOR/MEK pathway induces Bim/Mcl-1-regulated apoptosis in pancreatic cancer cells. Cancer biology & therapy, 20(1), 21.

Michael IP, et al. (2019) ALK7 Signaling Manifests a Homeostatic Tissue Barrier That Is Abrogated during Tumorigenesis and Metastasis. Developmental cell, 49(3), 409.

Guièze R, et al. (2019) Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies. Cancer cell, 36(4), 369.

Wang L, et al. (2018) Mitofusin 2 Regulates Axonal Transport of Calpastatin to Prevent Neuromuscular Synaptic Elimination in Skeletal Muscles. Cell metabolism, 28(3), 400.

Pan R, et al. (2017) Synthetic Lethality of Combined Bcl-2 Inhibition and p53 Activation in AML: Mechanisms and Superior Antileukemic Efficacy. Cancer cell, 32(6), 748.

Cao B, et al. (2016) Inactivation of oncogenic cAMP-specific phosphodiesterase 4D by miR-139-5p in response to p53 activation. eLife, 5.